Visit COVID-19 resources

[Skip to Content]

NICE guidance on Ocriplasmin

Sep 17

College Statement Ocriplasmin is a recombinant protease enzyme that is effective in lysing fibronectin and laminin bonds at the vitreoretinal interface thus relieving vitreoretinal traction following intravitreal injection. Pivotal phase III trials have shown its effectiveness in treating vitreomacular traction leading to European Union approval in March 2013. The Royal College of Ophthalmologists welcomes the

  • 17 September 2013

Updated Public Health Outcomes Framework eye health indicator figures

Aug 24

The Public Health Outcomes Framework (PHOF) eye health indicator figures have been updated New baseline data have been published for Preventable sight loss indicators(4.12 i “ Preventable sight loss – age related macular degeneration (AMD)”, 4.12 ii “ Preventable sight loss – glaucoma”, 4.12 iii “Preventable sight loss – diabetic eye disease”, 4.12 iv “Preventable

  • 24 August 2013

Positive draft final guidance from NICE for Eylea® for the treatment on wet AMD

May 31

College Statement The Royal College of Ophthalmologists welcomes the NICE draft final guidance which announces that Eylea® (aflibercept) should be recommended for the treatment of patients with wet age-related macular degeneration (wAMD). Eylea® is a soluble vascular endothelial growth factor (VEGF) receptor fusion protein which binds to all forms of VEGF and placental growth factor

  • 31 May 2013

Certificate of Fitness for Honorary Practice

May 29

NHS Employers and the Academy of Medical Royal Colleges (AoMRC) have agreed a  means by which consultants can carry out short-term, ad hoc or urgent activity in another organisation, without the need for an honorary contract of employment. Current practice for the short-term visit of a consultant involves obtaining a full honorary contract and verifying

  • 29 May 2013

Intravitreal Ranibizumab injection for treatment of MO secondary to RVO

May 16

College Statement The Royal College of Ophthalmologists welcomes the decision by the National Institute for Health and Care Excellence (NICE) to recommend 0.5mg ranibizumab intravitreal injection as an option for the treatment of macular oedema secondary to central retinal vein occlusion (CRVO) and selected cases of branch retinal vein occlusion (BRVO) when laser has either

  • 16 May 2013